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Design, synthesis and antitumor activities of ﬂuoroquinolone C-3 heterocycles (IV) 3131. Introduction
Rational mechanism-based drug design is an efﬁcient route for
the discovery of lead compounds1. An interesting example is the
use of prokaryotic type II topoisomerases (DNA gyrase and
topoisomerase IV) and eukaryotic type II topoisomerases as
cellular targets in the search for ﬂuoroquinolones with anti-
bacterial and anticancer activities respectively2. In view of the
mechanistic similarity and sequence homologies of the two
enzymes, many attempts have been made to modify antibacter-
ial ﬂuoroquinolones to produce novel antitumor drugs.3,4.
However, most of this research has focused on the C-7
piperazine ring of the ﬂuoroquinolone skeleton5 and little effort
has been devoted to the C-3 carboxylic acid group. Recently,
promising results of tests on compounds in which the carboxylic
acid group is replaced with s-triazole and its fused heterocyclic
ring have increased our interest in developing such compounds
as antitumor ﬂuoroquinolones6,7. Because Schiff bases8 and
Mannich bases9 are common pharmacophores in the design
and development of anticancer chemotherapeutic agents, we
now report the synthesis and antitumor activity of Schiff and
Schiff–Mannich base-substituted derivatives of compounds
produced by bioisosteric replacement of the C-3 carboxylic
acid group in oﬂoxacin 1 with an s-triazole ring (Scheme 1).2. Results and discussion
Oﬂoxacin hydrazide 2 was conveniently prepared by direct
hydrazinolysis of oﬂoxacin 1. A direct condensation of
hydrazide 2 with carbon disulﬁde in ethanol gave the corre-
sponding hydrazide carbodithioic acid 3 in better yield thanScheme 1 Synthetic route to Schiff (5a–5k) and Schiff–Mannich (6a
and 6: (a) H; (b) 4–CH3O; (c) 2–OH; (d) 2–CH3O; (e) 3,4–OCH2O; (f)
(j) 4–F; (k) 4–NO2.that produced in a general potassium hydroxide-catalyzed
procedure10. The key intermediate, C-3-(1-amino- 5-mercapto-
s-triazole) 4, was then successfully prepared by base-catalyzed
cyclo-condensation of 3 with hydrazine hydrate. Schiff base
reactions of 4 with aromatic aldehydes was carried out in
glacial acetic acid to form the respective Schiff bases 5.
Subsequent Mannich reactions with dimethylamine in glacial
acetic acid gave the compounds 6 bearing both functionalized
side chains of Schiff and Mannich bases.
The 1H NMR spectra of 6a–6k displayed three characteristic
one-proton signals at d 9.20–8.90 (s, 1H), 8.90 (s, 1H) and
5.20–5.10 (s, 1H) assigned to the 2-H of the ﬂuoroquinolone
scaffold, imino carbon–H of the Schiff-base (CH¼N) and
methylene–H of the Mannich-base (N–CH2), respectively. In
addition, a peak at d 2.30 (s, 6H) was assigned to the
dimethylamino carbon–H instead of the mercapto–H of 5 at
d 13.70 (s, 1H). In the mass spectra of compounds 5 and 6,
base peaks corresponded to the respective molecular ion peaks.
In vitro antitumor activity of compounds 5 and 6 against a
murine leukemia cell line (L1210), a human leukocytoma cell
line (HL60) and a Chinese hamster ovary cell line (CHO) was
evaluated using the MTT assay7. The results show that
compounds 6a–6k are signiﬁcantly more cytotoxic (IC50 values
of 0.14–17.6 mM) than their parent Schiff bases 5a–5k (IC50
values 10.5–50.2 mM) (Table 1). More interestingly, com-
pounds 5c, 5g, 5h, 6c, 6g and 6h possessing a free phenol
group exhibit more potent activity than the other tested
compounds. These preliminary results suggest that replace-
ment of the C-3 carboxylic group by a heterocycle modiﬁed by
two functionalized pharmacophores (in this case Schiff and
Mannich bases) is a promising strategy for the further
development of ﬂuoroquinolone anticancer agents.–6k) base-substituted s-triazole derivatives of oﬂoxacin 1. R in 5
3,4,5–(CH3O)3; (g) 3–OH–4–CH3O; (h) 4–OH–3–CH3O; (i) 4-Cl;
Table 1 Growth inhibitory activities of the compounds
(5a–5k and 6a–6k) against L1210, HL60 and CHO tumor
cells in the MTT assay (IC50 mM).
Compd. IC50 (mM)
L1210 HL60 CHO
5a 36.4 24.6 44.5
5b 18.7 13.8 25.7
5c 13.5 10.5 20.6
5d 26.7 13.7 38.4
5e 24.6 16.2 36.2
5f 38.2 17.7 48.7
5g 11.3 10.6 15.6
5h 14.8 9.4 16.8
5i 37.6 22.8 46.2
5j 24.6 17.4 37.5
5k 43.2 34.6 50.2
6a 14.6 11.4 17.6
6b 7.3 3.2 6.4
6c 6.8 0.14 1.7
6d 13.6 3.8 6.0
6e 14.7 4.2 5.8
6f 15.3 2.7 8.5
6g 6.2 0.62 1.2
6h 7.3 0.83 2.3
6i 14.3 5.7 7.4
6j 10.5 4.2 6.2
6k 14.6 12.4 15.3
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3.1. Chemistry
Melting points were determined in sealed capillaries and are
uncorrected. IR spectra were recorded on a Nicolet Impact
410 spectrometer; 1H NMR spectra on a Bruker AM-400
spectrometer; mass spectra on an Esquire LC instrument and
elemental analyses on a PE 2400-II instrument. Materials and
solvents were commercially available except where indicated
and were used as received.
3.1.1. 6-Fluoro-7-(4-methylpiperazin-1-yl)-1,8-(2,1-
oxypropyl)-quinolin-4(1H)-one-3-hydrazide (2)
A mixture of oﬂoxacin 1 (20.0 g, 55.0 mmol) and 85%
hydrazine hydrate (20.0 g, 340.0 mmol) was reﬂuxed for
24 h. The resulting precipitate was ﬁltered and recrystallized
from 95% ethanol (100 mL) to give 2: yield 67%, mp 207–
208 1C; 1H NMR (DMSO-d6, 400 MHz) d: 10.62 (s, 1H,
CONH), 8.97 (s, 1H, H-1), 7.62 (d, 1H, J¼13.0 Hz, H-5),
4.59–4.46 (m, 5H, OCH2CHN and NH2), 3.372.85 (m, 8H,
piperazine-H), 2.24 (s, 3H, N–CH3), 1.42 (d, J¼7.2 Hz, 3H,
CH3); IR (KBr) u: 3428, 3047, 1724, 1608, 1557, 1477 cm
1;
MS m/z: 376 [MþH]þ, calcd. 375.41 [M]þ. Analysis: calcd. for
C18H22FN5O3 C 57.59, H 5.91, N 18.66; found C 57.81, H
5.74, N 18.91.
3.1.2. 3-(4-Amino-5-mercapto-s-triazol-3-yl)-6-ﬂuoro-7-
(4-methylpiperazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-
one (4)
A mixture of compound 2 (10.0 g, 27.0 mmol) and carbon
disulﬁde (3.1 g, 30.0 mmol) in 95% ethanol (150 mL) wasreﬂuxed for 10 h. The resulting precipitate was ﬁltered and
washed with anhydrous ethanol to give the crude hydrazide
carbodithioic acid 3. It was immediately dissolved in a
solution containing 85% hydrazine hydrate (20.0 g,
340.0 mmol) and 40% sodium hydroxide (3.0 g, 30.0 mmol)
and reﬂuxed for 12 h. After removal of solvent, water
(200 mL) and activated charcoal (0.5 g) were added to the
residue and the mixture reﬂuxed for 1 h. After removing
charcoal, the ﬁltrate pH was adjusted to pH 8.0 using
concentrated HCl and the resultant precipitate was collected
and recrystallized from DMF-ethanol to give a yellow solid 4:
Yield 72%, mp4260 1C; 1H NMR (DMSO-d6, 400 MHz) d:
13.62 (s, 1H, SH), 9.03 (s, 1H, H-2), 7.68 (d, 1H, J¼13.0 Hz,
H-5), 5.56 (s, 2H, NH2), 4.574.48 (m, 3H, OCH2CHN),
3.52–3.36 (m, 8H, piperazine-H), 2.28 (s, 3H, N-CH3), 1.44 (d,
J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3447, 3056, 1668, 1617,
1563, 1467 cm1; MS m/z: 432 [MþH]þ, calcd. 431.50 [M]þ.
Analysis: Calcd. for C19H22FN7O2S C 52.89, H 5.14, N 22.72;
found C.53.04, H 4.95, N 22.58.3.1.3. General synthetic procedure for Schiff bases: 3-(4-
substituted benzylideneamino-5-mercapto-s-triazol-3-yl)-6-
ﬂuoro-7-(4-methylpiperazin-1-yl)-1,8-(2,1-oxypropyl)-
quinolin-4(1H)-one (5a–5k)
A mixture of 4 (1.0 g, 2.3 mmol) and an aromatic aldehyde
(2.5 mmol) in glacial acetic acid (15 mL) was reﬂuxed for 24 h.
After removal of the solvent under reduced pressure, the
residue was dissolved in DMF-ethanol and the resulting
precipitates Schiff bases 5a–5k were collected.
3-(4-Benzylideneamino)-5-mercapto-s-triazol-3-yl)-6-ﬂuoro-
7-(4-methylpiperazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-one
(5a): yield 84%, mp 4250 1C; 1H NMR (DMSO-d6,
400 MHz) d: 13.67 (s, 1H, SH), 9.08 (s, 1H, H-2), 8.86
(s, 1H, CH¼N), 7.74–7.63 (m, 4H, H-5 and Ph-H), 7.56
(d, J¼7.2 Hz, 2H, Ph-H), 4.54–4.46 (m, 3H, OCH2 CHN),
3.55–3.37 (m, 8H, piperazine-H), 2.32 (s, 3H, N–CH3), 1.46
(d, J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3356, 3047, 1643, 1624,
1566, 1457 cm1; MS m/z: 520 [MþH]þ, calcd. 519.61 [M]þ.
Analysis: calcd. for C26H26FN7O2S C 60.10, H 5.04, N 18.87;
found C 60.33, H 4.92, N 19.10.
3-[4-(4-Methyloxy-benzylideneamino)-5-mercapto-s-triazol-
3-yl]-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-1,8-(2,1-oxypropyl)-
quinolin-4(1H)-one (5b): yield 77%, mp 4250 1C; 1H NMR
(DMSO-d6, 400 MHz) d: 13.68 (s, 1H, SH), 9.12 (s, 1H, H-2),
8.87 (s, 1H, CH¼N), 7.82 (d, J¼7.4 Hz, Ph–H), 7.68 (d,
J¼13.2 Hz, 1H, H-5), 7.57 (d, J¼7.4 Hz, 2H, Ph–H), 4.56–
4.45 (m, 3H, OCH2 CHN), 3.86 (s, 3H, CH3O), 3.57–3.32 (m,
8H, piperazine-H), 2.34 (s, 3H, N–CH3), 1.48 (d, J¼7.2 Hz,
3H, CH3); IR (KBr) u: 3372, 3063, 1646, 1621, 1557,
1256 cm1; MS m/z: 550 [MþH]þ, calcd. 549.63 [M]þ. Ana-
lysis: calcd. for C27H28FN7O3S C 59.00, H 5.13, N 17.84;
found C 59.26, H 4.94, N 19.12.
3-[4-(2-Hydroxy-benzylideneamino)-5-mercapto-s-triazol-3-
yl]-6-ﬂuoro-7-(4-methylpiper-azin-1-yl)-1,8-(2,1-oxypropyl)-quino-
lin-4(1H)-one (5c): yield 68%, mp 243–245 1C; 1H NMR
(DMSO-d6, 400 MHz) d: 13.65 (s, 1H, SH), 9.17 (s, 1H,
OH), 9.10 (s, 1H, H-2), 8.89 (s, 1H, CH¼N), 7.83–7.52 (m,
5H, H-5 and Ph–H), 4.62–4.52 (m, 3H, OCH2 CHN), 3.52–
3.34 (m, 8H, piperazine–H), 2.30 (s, 3H, N–CH3), 1.45 (d,
J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3438, 2894, 1644, 1627,
1563, 1238 m1; MS m/z: 536 [MþH]þ, calcd. 535.60 [M]þ.
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found C 58.52, H 4.71, N 18.54.
3-[4-(2-Methyloxy-benzylideneamino)-5-mercapto-s-triazol-
3-yl]-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-1,8-(2,1-oxypropyl)-
quinolin-4(1H)-one (5d): yield 58%, mp 230–232 1C; 1H
NMR (DMSO-d6, 400 MHz) d: 13.66 (s, 1H, SH), 8.89–
8.86 (br, 2H, H-2 and CH¼N), 7.72–7.53 (m, 5H, H-5 and
Ph–H), 4.57–4.43 (m, 3H, OCH2 CHN), 3.82 (s, 3H, OCH3),
3.47–3.25 (m, 8H, piperazine–H), 2.28 (s, 3H, N–CH3), 1.43
(d, J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3258, 3052, 1637, 1624,
1555, 1235 cm1; MS m/z: 550 [MþH]þ, calcd. 549.63 [M]þ.
Analysis: calcd. for C27H28FN7O3S C 59.00, H 5.13, N 17.84;
found C 59.26, H 4.91, N 18.04.
3-[4-(3,4-Oxymethyloxy-benzylideneamino)-5-mercapto-
s-triazol-3-yl]-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-1,8-(2,1-
oxypropyl)-quinolin-4(1H)-one (5e): yield 84%, mp 4250 1C;
1H NMR (DMSO-d6, 400 MHz) d: 13.67 (s, 1H, SH), 9.05
(s, 1H, H-2), 8.86 (s, 1H, CH¼N), 7.85–7.57 (m, 4H, H-5 and
Ph–H), 6.12 (s, 2H, OCH2O), 4.56–4.47 (m, 3H, OCH2 CHN),
3.55–3.32 (m, 8H, piperazine–H), 2.32 (s, 3H, N–CH3), 1.48
(d, J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3347, 2956, 1640, 1633,
1567, 1236 cm1; MS m/z: 564 [MþH]þ, calcd. 563.62 [M]þ.
Analysis: calcd. for C27H26FN7O4S C 57.54, H 4.65, N 17.40;
found C 57.72, H 4.48, N 17.63.
3-{4-[3,4,5-Trimethyloxy-benzylideneamino]-5-mercapto-s-
triazol-3-yl}-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-1,8-(2,1-oxy-
propyl)-quinolin-4(1H)-one (5f): yield 68%, mp 4250 1C; 1H
NMR (DMSO-d6, 400 MHz) d: 13.57 (s, 1H, SH), 9.13 (s, 1H,
H-2), 8.88 (s, 1H, CH¼N), 7.83 (s, 2H, Ph–H), 7.76
(d, J¼13.0 Hz, H-5), 4.56–4.45 (m, 3H, OCH2 CHN), 3.82
(s, 9H, 3OCH3), 3.56–3.28 (m, 8H, piperazine–H), 2.30 (s,
3H, N–CH3), 1.46 (d, J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3354,
3028, 1644, 1627, 1558, 1228 cm1; MS m/z: 610 [MþH]þ,
calcd. 609.68 [M]þ. Analysis: calcd. for C29H32FN7O5S C
57.13, H 5.29, N 16.08; found C 57.37, H 5.36, N 16.36.
3-[4-(3-Hydroxy-4-methyloxy-benzylideneamino)-5-merc-
apto-s-triazol-3-yl]-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-1,8-
(2,1-oxypropyl)-quinolin-4(1H)-one (5g): yield 73%, mp
4250 1C; 1H NMR (DMSO-d6, 400 MHz) d: 13.64 (s, 1H,
SH), 9.18 and 9.14 (s, 2H, OH and H-2), 8.86 (s, 1H,
CH¼N), 7.80–7.55 (m, 4H, H-5 and Ph-H), 3.89 (s,
3H, CH3O), 4.57–4.43 (m, 3H, OCH2 CHN), 3.57–3.31
(m, 8H, piperazine-H), 2.34 (s, 3H, N-CH3), 1.50 (d,
J¼7.0 Hz,, 3H, CH3); IR (KBr) u: 3362, 3038, 1636, 1624,
1557, 1445 cm1; MS m/z: 567 [MþH]þ, calcd. 565.63 [M]þ.
Analysis: calcd. for C27H28FN7O4S C 57.33, H 4.99, N
17.33; found C 57.58, H 4.78, N 17.56.
3-[4-(3-Methyloxy-4-hydroxy-benzylideneamino)-5-merca-
pto-s-triazol-3-yl]-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-1,8-(2,
1-oxypropyl)-quinolin-4(1H)-one (5h): yield 62%, mp 241–
243 1C; 1H NMR (DMSO-d6, 400 MHz) d: 13.62 (s, 1H, SH),
9.17 and 9.06 (s, 2H, OH and H-2), 8.84 (s, 1H, CH¼N),
7.78–7.52 (m, 4H, H-5 and Ph-H), 3.87 (s, 3H, CH3O), 4.55–
4.42 (m, 3H, OCH2 CHN), 3.55–3.27 (m, 8H, piperazine-H),
2.32 (s, 3H, N-CH3), 1.47 (d, J¼7.2 Hz, 3H, CH3); IR (KBr)
u: 3352, 3045, 1634, 1626, 1560, 1447 cm1; MS m/z: 567
[MþH]þ, calcd. 565.63 [M]þ. Analysis: calcd. for C27H28
FN7O4S C 57.33, H 4.99, N 17.33; found C 57.54, H 4.71,
N 17.58.
3-[4-(4-Chloro-benzylideneamino)-5-mercapto-s-triazol-3-
yl]-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-1,8-(2,1-oxypropyl)-qui
nolin-4(1H)-one (5i): yield 78%, mp 236–238 1C; 1H NMR(DMSO-d6, 400 MHz) d: 13.68 (s, 1H, SH), 9.16 (s, 1H, H-2),
8.92 (s, 1H, CH¼N), 7.82 (d, J¼7.5 Hz, 2H, Ph-H), 7.72
(d, J¼13.0 Hz, 1H, H-5), 7.66 (d, J¼7.5 Hz, 2H, Ph-H), 4.58–
4.46 (m, 3H, OCH2 CHN), 3.62–3.35 (m, 8H, piperazine-H),
2.36 (s, 3H, N-CH3), 1.52 (d, J¼7.2 Hz, 3H, CH3); IR (KBr)
u: 3345, 3047, 1638, 1626, 1557, 1446 cm1; MS m/z: 554
for Cl35 [MþH]þ, calcd. 554.05 [M]þ. Analysis: calcd. for
C26H25ClFN7O2S C 56.36, H 4.55, N 17.70; found C 56.50, H
4.34, N 17.91.
3-[4-(4-Fluoro-benzylideneamino)-5-mercapto-s-triazol-3-yl]-
6-ﬂuoro-7-(4-methylpiperazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-
4(1H)-one (5j): yield 83%, mp 4250 1C; 1H NMR (DMSO-d6,
400 MHz) d: 13.72 (s, 1H, SH), 9.18 (s, 1H, H-2), 8.94 (s, 1H,
CH¼N), 7.86 (d, J¼7.5 Hz, 2H, Ph-H), 7.78 (d, J¼13.0 Hz,
1H, H-5), 7.64 (d, J¼7.5 Hz, 2H, Ph-H), 4.62–4.47 (m, 3H,
OCH2 CHN), 3.58–3.32 (m, 8H, piperazine-H), 2.37 (s, 3H, N-
CH3), 1.54 (d, J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3328, 3057,
1646, 1637, 1561, 1457 cm1; MS m/z: 538 [MþH]þ, calcd.
537.60 [M]þ. Analysis: calcd. for C26H25F2N7O2S C 58.09, H
4.69, N 18.24; found C 58.35, H 4.47, N 18.50.
3-[4-(4-Nitro-benzylideneamino)-5-mercapto-s-triazol-3-yl]-6-ﬂu
oro-7-(4-methylpiperazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-
one (5k): yield 64%, mp 4250 1C; 1H NMR (DMSO-d6,
400 MHz) d: 13.76 (s, 1H, SH), 9.21 (s, 1H, H-2), 8.97 (s, 1H,
CH¼N), 7.88 (d, J¼7.5 Hz, 2H, Ph–H), 7.80 (d, J¼13.0 Hz, 1H,
H-5), 7.68 (d, J¼7.5 Hz, 2H, Ph–H), 4.66–4.52 (m, 3H, OCH2
CHN), 3.56–3.28 (m, 8H, piperazine–H), 2.36 (s, 3H, N-CH3),
1.55 (d, J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3348, 3046, 1642, 1634,
1557, 1238 cm1; MS m/z: 556 [MþH]þ, calcd. 564.60 [M]þ.
Analysis: calcd. for C26H25FN8O4S C 55.31, H 4.46, N 19.85;
found C 55.50, H 4.28, N 20.11.3.1.4. General synthetic procedure for Schiff–Mannich bases:
3-(4-substituted benzylidene-amino-2-dimethylaminomethyl-2,4-
dihydro-s-triazole-3-thione-5-yl)-6-ﬂuoro-7-(4-methylpiperazin-
1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-one (6a–6k)
A mixture of 5 (1.0 mmol) and dimethylamine hydrochloride
(0.1 g, 1.2 mmol) in methanol (10 mL) was reﬂuxed for 1 h
after which 37% formaldehyde (0.5 mL) was added and the
mixture was reﬂuxed for 12 h. After removal of solvent under
reduced pressure, the residue was dissolved in water (10 mL),
the pH was adjusted to pH 8.0 using ammonia and the liquid
was extracted with chloroform. The dried extract was evapo-
rated in vacuo and the residue was recrystallized from ethanol
to give the Schiff–Mannich bases 6a–6k.
3-(4-Benzylideneamino-2-dimethylaminomethyl-2,4-dihydro-s-
triazole-3-thione-5-yl)-6-ﬂuoro-7-(4-methylpiperazin-1-yl)-1,8-(2,
1-oxypropyl)-quinolin-4(1H)-one (6a): yield 84%, mp 226–
228 1C; 1H NMR (DMSO-d6, 400 MHz) d: 9.12 (s, 1H, H-2),
8.88 (s, 1H, CH¼N), 7.80–7.62 (m, 4H, H-5 and Ph–H), 7.57 (d,
J¼7.2 Hz, 2H, Ph–H), 5.12 (s, 2H, NCH2), 4.56–4.47 (m, 3H,
OCH2 CHN), 3.53–3.34 (m, 8H, piperazine-H), 2.34–2,26
(br, 9H, 3N–CH3), 1.48 (d, J¼7.2 Hz, 3H, CH3); IR
(KBr) u: 3357, 3062, 1642, 1626, 1557, 1326, 1227 cm1; MS
m/z: 577 [MþH]þ, calcd. 576.70 [M]þ. Analysis: calcd. for
C29H33FN8O2S C 60.40, H 5.77, N 19.43; found C 60.62, H
5.54, N 19.68.
3-[4-(4-Methyloxy-benzylideneamino)-2-dimethylaminomet
hyl-2,4-dihydro-s-triazole-3-thione-5-yl]-6-ﬂuoro-7-(4-methylp
iperazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-one-quino-
lin-4(1H)-one (6b): yield 75%, mp 238–241 1C; 1H NMR
Guoqiang Hu et al.316(DMSO-d6, 400 MHz) d: 9.14 (s, 1H, H-2), 8.92 (s, 1H,
CH¼N), 7.84 (d, J¼7.4 Hz, Ph–H), 7.72 (d, J¼13.2 Hz,
1H, H-5), 7.63 (d, J¼7.4 Hz, 2H, Ph-H), 4.62–4.46 (m, 3H,
OCH2 CHN), 3.88 (s, 3H, CH3O), 3.56–3.30 (m, 8H, piper-
azine-H), 2.32–3.18 (s, 9H, N–CH3), 1.52 (d, J¼7.2 Hz, 3H,
CH3); IR (KBr) u: 3368, 3047, 1644, 1626, 1558, 1328,
1224 cm1; MS m/z: 607 [MþH]þ, calcd. 606.73 [M]þ. Ana-
lysis: calcd. for C30H35FN8O3S C 59.39, H 5.81, N 18.47;
found C 59.57, H 5.72, N 18.68.
3-[4-(2-Hydroxy-benzylideneamino)-2-dimethylaminometh-
yl-2,4-dihydro-s-triazole-3-thione-5-yl]-6-ﬂuoro-7-(4-methylpi-
perazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-one (6c): yi-
eld 62%, mp 231–232 1C; 1H NMR (DMSO-d6, 400 MHz) d:
9.15–9.11 (br, 2H, OH and H-2), 8.92 (s, 1H, CH¼N), 7.86–
7.60 (m, 5H, H-5 and Ph-H), 4.63–4.55 (m, 3H, OCH2CHN),
3.57–3.32 (m, 8H, piperazine–H), 2.32–2.26 (br, 9H, 3N–
CH3), 1.47 (d, J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3445, 3027,
1646, 1558, 1327, 1236 cm1; MS m/z: 593 [MþH]þ, calcd.
592.70 [M]þ. Analysis: calcd. for C29H33FN8O3S C 58.77, H
5.61, N 18.91; found C 58.94, H 5.40, N 19.17.
3-[4-(2-Methyloxy-benzylideneamino)-2-dimethylaminomethyl-
2,4-dihydro-s-triazole-3-thione-5-yl]-6-ﬂuoro-7-(4-methylpiperazin-
1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-one (6d): yield 58%, mp
218–220 1C; 1H NMR (DMSO-d6, 400 MHz) d: 9.02–8.87 (br,
2H, H-2 and CH¼N), 7.82–7.58 (m, 5H, H-5 and Ph–H), 4.56–
4.53 (m, 3H, OCH2CHN), 3.87 (s, 3H, CH3O), 3.54–3.30 (m, 8H,
piperazine–H), 2.30–2.25 (br, 9H, 3N–CH3), 1.45 (d, J¼7.2 Hz,
3H, CH3); IR (KBr) u: 3358, 3017, 1638, 1557, 1328, 1234 cm
1;
MS m/z: 607 [MþH]þ, calcd. 606.73 [M]þ. Analysis: calcd. for
C30H35FN8O3S C 59.39, H 5.81, N 18.47; found C 59.54, H 5.66,
N 18.72.
3-[4-(3,4-Oxymethyloxy-benzylideneamino)-2-dimethylami-
nomethyl-2,4-dihydro-s-triazole-3-thione-5-yl]-6-ﬂuoro-7-(4-
methylpiperazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-one
(6e): yield 81%, mp 243–245 1C; 1H NMR (DMSO-d6,
400 MHz) d: 9.10 (s, 1H, H-2), 8.93 (s, 1H, CH¼N), 7.86–
7.66 (m, 4H, H-5 and Ph–H), 6.23 (s, 2H, OCH2O), 4.62–4.43
(m, 3H, OCH2 CHN), 3.57–3.35 (m, 8H, piperazine–H), 2.33–
2.26 (br, 9H, 3N–CH3), 1.54 (d, J¼7.2 Hz, 3H, CH3); IR
(KBr) u: 3358, 2987, 1644, 1554, 1326, 1224 cm1; MS m/z:
621 [MþH]þ, calcd. 620.71 [M]þ. Analysis: calcd. for
C30H33FN8O4S C 58.05, H 5.36, N 18.05; found C 58.27, H
5.12, N 18.31.
3-{4-[3,4,5-Trimethyloxy-benzylideneamino]-2-dimethylaminom
ethyl-2,4-dihydro-s-triazole-3-thione-5-yl}-6-ﬂuoro-7-(4-methylpip-
erazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-one (6f): yield
72%, mp 225–227 1C; 1H NMR (DMSO-d6, 400MHz) d: 9.15
(s, 1H, H-2), 8.93 (s, 1H, CH¼N), 7.86 (s, 2H, Ph–H), 7.78 (d,
J¼13.0 Hz, H-5), 3.86 (s, 9H, 3OCH3), 4.57–4.42 (m, 3H,
OCH2CHN), 3.56–3.23 (m, 8H, piperazine–H), 2.30–2.26 (br, 9H,
N–CH3), 1.52 (d, J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3348, 3037,
1642, 1556, 1327, 1235 cm1; MS m/z: 667 [MþH]þ, calcd. 666.78
[M]þ. Analysis: calcd. for C32H39FN8O5S C 57.64, H 5.90, N
16.81; found C 57.88, H 5.63, N 16.92.
3-[4-(3-Hydroxy-4-methyloxy-benzylideneamino)-2-dime-
thylaminomethyl-2,4-dihydro-s-triazole-3-thione-5-yl]-6-ﬂu-
oro-7-(4-methylpiperazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-
4(1H)-one (6g): yield 86%, mp 253–255 1C; 1H NMR
(DMSO-d6, 400 MHz) d: 9.20–9.13 (br, 2H, OH and H-2),
8.92 (s, 1H, CH¼N), 7.83–7.61 (m, 4H, H-5 and Ph-H), 3.88
(s, 3H, CH3O), 4.62–4.46 (m, 3H, OCH2 CHN), 3.55–3.30
(m, 8H, piperazine–H), 2.35–2.28 (s, 9H, 3N–CH3), 1.53(d, J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3352, 3047, 1644, 1627,
1557, 1335, 1238 cm1; MS m/z: 623 [MþH]þ, calcd. 622.73
[M]þ. Analysis: calcd. for C30H35FN8O4S C 57.86, H 5.67, N
17.99; found C 57.94, H 5.41, N 18.23.
3-[4-(3-Methyloxy-4-hydroxy-benzylideneamino)-2-
dimethylaminomethyl-2,4-dihydro-s-triazole-3-thione-5-yl]-6-
ﬂuoro-7-(4-methylpiperazin-1-yl)-1,8-(2,1-oxypropyl)-quino-
lin-4(1H)-one (6h): yield 61%, mp 238–240 1C; 1H NMR
(DMSO-d6, 400 MHz) d: 9.16–9.10 (br, 2H, OH and H-2),
8.87 (s, 1H, CH¼N), 7.80–7.57 (m, 4H, H-5 and Ph-H), 3.86
(s, 3H, CH3O), 4.58–4.45 (m, 3H, OCH2 CHN), 3.53–3.25 (m,
8H, piperazine–H), 2.32–2.28 (s, 9H, 3N–CH3), 1.51 (d,
J¼7.2 Hz, 3H, CH3); IR (KBr) u: 3347, 3038, 1642, 1630,
1556, 1327, 1236 cm1; MS m/z: 623 [MþH]þ, calcd. 622.73
[M]þ. Analysis: calcd. for C30H35FN8O4S C 57.86, H 5.67, N
17.99; found C 58.07, H 5.44, N 18.25.
3-[4-(4-Chloro-benzylideneamino)-2-dimethylaminomethyl-
2,4-dihydro-s-triazole-3-thione-5-yl]-6-ﬂuoro-7-(4-methylpi-
perazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-one (6i):
yield 68%, mp 221–223 1C; 1H NMR (DMSO-d6, 400 MHz)
d: 9.18 (s, 1H, H-2), 8.94 (s, 1H, CH¼N), 7.86 (d, J¼7.5 Hz,
2H, Ph–H), 7.74 (d, J¼13.0 Hz, 1H, H-5), 7.62 (d, J¼7.5 Hz,
2H, Ph–H), 4.64–4.45 (m, 3H, OCH2CHN), 3.63–3.36 (m, 8H,
piperazine-H), 2.34–2.30 (br, 9H, 3N–CH3), 1.55 (d, J¼7.2
Hz, 3H, CH3); IR (KBr) u: 3328, 3057, 1642, 1562, 1336,
1238 cm1; MS m/z: 611 for Cl35 [MþH]þ, calcd. 611.15 [M]þ.
Analysis: calcd. for C29H32ClFN8O2S C 57.00, H 5.28, N
18.33; found C 57.26, H 5.14, N 18.51.
3-[4-(4-Fluoro-benzylideneamino)-2-dimethylaminomethyl-
2,4-dihydro-s-triazole-3-thione-5-yl]-6-ﬂuoro-7-(4-methylpi-
perazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-one (6j):
yield 84%, mp 236–239 1C; 1H NMR (DMSO-d6, 400 MHz)
d: 9.21 (s, 1H, H-2), 8.96 (s, 1H, CH¼N), 7.88 (d, J¼7.5 Hz,
2H, Ph–H), 7.80 (d, J¼13.0 Hz, 1H, H-5), 7.66 (d, J¼7.5 Hz,
2H, Ph–H), 4.65–4.48 (m, 3H, OCH2CHN), 3.62–3.35 (m, 8H,
piperazine-H), 2.42–2.32 (s, 3H, N–CH3), 1.57 (d, J¼7.2 Hz,
3H, CH3); IR (KBr) u: 3345, 3007, 1642, 1558, 1337,
1230 cm1; MS m/z: 595 [MþH]þ, calcd. 594.69 [M]þ. Ana-
lysis: calcd. for C29H32F2N8O2S C 58.57, H 5.42, N 18.84;
found C 58.82, H 5.18, N 19.13.
3-[4-(4-Nitro-benzylideneamino)-2-dimethylaminomethyl-
2,4-dihydro-s-triazole-3-thione-5-yl]-6-ﬂuoro-7-(4-methylpi-
perazin-1-yl)-1,8-(2,1-oxypropyl)-quinolin-4(1H)-one (6k):
yield 72%, mp 4250 1C; 1H NMR (DMSO-d6, 400 MHz) d:
9.24 (s, 1H, H-2), 9.03 (s, 1H, CH¼N), 7.91 (d, J¼7.5 Hz,
2H, Ph-H), 7.84 (d, J¼13.0 Hz, 1H, H-5), 7.72 (d, J¼7.5 Hz,
2H, Ph–H), 4.68–4.53 (m, 3H, OCH2 CHN), 3.61–3.32 (m,
8H, piperazine-H), 2.38–2.30 (s, 3H, N–CH3), 1.57 (d, J¼7.2
Hz, 3H, CH3); IR (KBr) u: 3347, 3027, 1645, 1556, 1327,
1235 cm1; MS m/z: 622 [MþH]þ, calcd. 621.70 [M]þ. Ana-
lysis: calcd. for C29H32FN9O4S C 56.03, H 5.19, N 20.28;
found C 56.25, H 5.43, N 20.60.3.2. MTT assay
The tumor cell lines, L1210, HL60 and CHO were maintained
in RPMI 1640 medium supplemented with 10% heat-inacti-
vated fetal bovine serum. Medium containing 5 103 cells was
seeded into each well of a 96-well microplate and the tested
compounds were added at concentrations of 0.1, 1.0, 10.0,
30.0 and 50.0 mM to triplicate wells before making the ﬁnal
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in a humidiﬁed atmosphere (5% CO2, 95% air) after which
100 mL methylthiazole trazolium (MTT) solution (1.0 mg/mL
in phosphate-buffered saline lacking calcium and magnesium)
was added to each well. After a further incubation for 4 h at
37 1C, 100 mL DMSO was added to wells containing CHO
cells and 10% sodium dodecylbenzenesulfonate was added to
wells containing L1210 and HL60 cells to solubilize any MTT-
formazan produced. The optical density (OD) of each well was
measured at 570 nm (OD570) with a microplate reader and the
inhibition of cell growth was calculated as (1T/C) 100%,
where C is the mean OD570 of the control group and T is that
of the treated group. The IC50 was determined from the
concentration–response data.
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